Pediatria
Aulas presenciais e o risco de transmissão domiciliar de COVID-19 – “Embora as aulas presenciais sejam associadas a risco de transmissão domiciliar de Covid-19, este risco pode ser bastante controlado com medidas adequadas de prevenção implementadas na escola”
30 Abr, 2021 | 08:51hHousehold COVID-19 risk and in-person schooling – Science
Comunicado de Imprensa: In-Person Schooling with Inadequate Mitigation Measures Raises Household Member’s COVID-19 Risk – Johns Hopkins Bloomberg School of Public Health
Comentário no Twitter
After analyzing responses from the #COVID19 Symptom Survey, @JustinLessler et al. find support for the idea that in-person schooling increases COVID-19 risk to household members; but also evidence that common mitigation measures can reduce this risk. https://t.co/DFtCoN0FEE pic.twitter.com/gxt7nkhdMb
— Science Magazine (@ScienceMagazine) April 29, 2021
Estudo de coorte: Associação entre infecção materna por SARS-Cov-2 durante a gravidez e desfechos neonatais – “embora bebês nascidos de mães positivas para o vírus sejam mais propensos a partos prematuros, pouquíssimos foram infectados pela COVID-19”
30 Abr, 2021 | 08:48hAssociation of Maternal SARS-CoV-2 Infection in Pregnancy With Neonatal Outcomes – JAMA
Comunicado de Imprensa: Low risk of infection in babies born to mothers with COVID-19 – Karolinska Institutet
Editorial: Understanding Risk for Newborns Born to SARS-CoV-2–Positive Mothers – JAMA
Comentário no Twitter
Maternal #SARSCoV2 infection in pregnancy was significantly associated with small increases in the absolute risk of respiratory disorders and some other neonatal morbidities https://t.co/ANkXkaxnwp
— JAMA (@JAMA_current) April 29, 2021
Estudo observacional: Intervenções de melhoria de qualidade hospitalar reduziram as taxas de parto cesariano em nulíparas, com gestação a termo, de feto único e em apresentação cefálica
29 Abr, 2021 | 09:52hHospital Quality Improvement Interventions, Statewide Policy Initiatives, and Rates of Cesarean Delivery for Nulliparous, Term, Singleton, Vertex Births in California – JAMA (gratuito por período limitado)
Editorial: Initiatives to Reduce Cesarean Delivery Rates for Low-risk First Births – JAMA
Comentário no Twitter (fio – clique para saber mais)
"Rates of cesarean delivery for NTSV births in California decreased [from 26% to 22.8%] in the setting of a coordinated hospital-level collaborative and statewide initiatives designed to support vaginal birth.
"The rest of the US had no change."https://t.co/jwKkQZ4nix @cmqcc
— Ben Harder #BlackLivesMatter (@benharder) April 27, 2021
Podcast: Doença cardíaca congênita para pediatras gerais
29 Abr, 2021 | 09:46h#24: Congenital Heart Disease for the General Pediatrician – The Cribsiders
Desafios da terapia intensiva pediátrica decorrentes dos efeitos indiretos da pandemia de COVID-19
28 Abr, 2021 | 08:55h
Comentário no Twitter
Impact of #COVID19 #pandemic on #PedsICU: less visible vs adult ICU but all-pervasive, substantial & likely long-lasting
➡️on children
➡️on families
➡️on organizations
➡️on PICU team@Dr_Hari_Krishna @PollakUri Shekerdemian L #FOAMcc #COVIDFOAM on @yourICM https://t.co/OyI9etm1a2 pic.twitter.com/1bqi1oKlMk— Intens Care Med (@yourICM) April 27, 2021
Ponto de Vista | Evidências de pesquisas em adultos incorporadas na pesquisa e na prática pediátricas: projetos bayesianos para agilizar a obtenção de evidências específicas para crianças
27 Abr, 2021 | 17:30h
Os serviços de imunização começam a se recuperar lentamente dos transtornos causados pela COVID-19, no entanto, milhões de crianças permanecem sob risco de doenças letais – WHO, UNICEF, Gavi
27 Abr, 2021 | 17:01hRelatório relacionado: Disability considerations for COVID-19 vaccination: WHO and UNICEF policy brief, 19 April 2021 – World Health Organization
Comentário no Twitter
While immunization services begin slow recovery from #COVID19, millions of children around the 🌍🌏🌎 remain vulnerable to deadly diseases.
More info 👉https://t.co/YjskC8z6nc pic.twitter.com/SEv8d2VSAB
— World Health Organization (WHO) (@WHO) April 26, 2021
Opinião | Dados do mundo real, e não previsões, deveriam direcionar as decisões sobre Covid-19 e reabertura de escolas
27 Abr, 2021 | 15:48hReal-world data, not predictions, should drive decisions on Covid-19 and school opening – STAT
Comentário do autor no Twitter
Real-world data, not predictions, should drive decisions on Covid-19 and school opening with @elbeezuchdt @citizen_oregon: Concept is simple. Schools are half/closed due to alarmist inaccurate models. Use real-world data to drive our decisions on kids.https://t.co/HfZl8IAVXq
— Monica Gandhi MD, MPH (@MonicaGandhi9) April 23, 2021
Estudo de caso-controle: Vacina Meningocócica B previna a doença com 79% de efetividade em crianças e adultos jovens
6 Dez, 2020 | 21:40hComentário: Meningococcus B vaccine prevents disease with 79 per cent effectiveness in under-18s – University of Bristol
Comentário no Twitter
In this matched case-control study, children who developed meningococcal disease were less likely to have been vaccinated with 4CMenB vs matched controls without meningococcal disease during the first 5y of vaccine availability in Portugal https://t.co/dGagZ3aTIB @adamhfinn
— JAMA (@JAMA_current) December 3, 2020
[Preprint] Estudo SOLIDARITY da OMS: Remdesivir, Hidroxicloroquina, Lopinavir e Interferon-β1a não melhoram o prognóstico em pacientes hospitalizados por Covid-19
16 Out, 2020 | 12:29hO Estudo SOLIDARITY da Organização Mundial de Saúde é o maior estudo testando terapêuticas para o Covid-19. Neste estudo randomizado multicêntrico envolvendo 11266 pacientes em 30 países, nenhuma das medicações diminuiu mortalidade ou outros desfechos clínicos relevantes, como necessidade de ventilação mecânica e tempo de internação hospitalar.
Fonte:
Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results – medRxiv
Comunicado de imprensa da OMS:
Comentário:
Remdesivir and interferon fall flat in WHO’s megastudy of COVID-19 treatments – Science
Comentários no Twitter:
Results of the @WHO SOLIDARITY trial:
4 drugs tested in 11,266 patients with COVID in 405 hospitals in 30 countries:
– hydroxychloroquine
– lopinavir
– remdesevir
– interferonNo clear benefit of any of them on survival. https://t.co/ohtTAFaSnc pic.twitter.com/2fO9E8zs8h
— Martin Landray (@MartinLandray) October 16, 2020
This is blockbuster from @WHO: 'Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens have little or no effect on hospitalized COVID-19, as indicated by mortality, initiation of ventilation and duration of hospital stay. @medrxivpreprint https://t.co/aNGLzLL5uW pic.twitter.com/daOAMVW62u
— Harlan Krumholz (@hmkyale) October 15, 2020